少即是多?比较正中胸骨切开与侧开胸行左心室辅助装置植入对术后结局与瓣膜病变的影响
该回顾性研究分析222例HeartMate3左心室辅助装置植入患者,侧开胸60例(27%),正中胸骨切开162例(73%),倾向评分匹配后比较45例侧开胸与68例正中胸骨切开。侧开胸组早期右心衰竭显著更少(24.4% vs 53.7%,P=.004),但随访期三尖瓣反流更多(17.6% vs 0%,P=.030)且容量负荷再入院率更高(Gray检验P=.0005)。作者认为侧开胸是安全但未必优于正中胸骨切开的替代方案。
要点
- 侧开胸组早期右心衰竭发生率显著低于正中胸骨切开组(24.4% vs 53.7%,P=.004)。
- 侧开胸组随访期三尖瓣反流发生率高于正中胸骨切开组(17.6% vs 0%,P=.030)。
- 侧开胸组容量负荷再入院率高于正中胸骨切开组(Gray检验P=.0005)。
核心结论
- 作者认为侧开胸是HeartMate3植入围术期和术后安全但未必优于正中胸骨切开的替代方案,因其无法同期行三尖瓣修复,可能增加晚期三尖瓣反流和容量负荷再入院风险。
研究设计与样本
- 回顾性分析2014年11月至2021年11月期间222例植入HeartMate3(Abbott Lab)左心室辅助装置的成年患者,按手术入路分层并在倾向评分匹配组中评估结局。
主要发现
- 队列中侧开胸60例(27%),正中胸骨切开162例(73%);倾向评分匹配比较侧开胸45例与正中胸骨切开68例。
- ICU停留时间(中位数10 vs 11天,P=.58)、住院时间(中位数46 vs 40天,P=.279)、拔管时间(中位数2天,P=.627)、ICU到达时血管活性-正性肌力评分(18.20 vs 16.60,P=.654)及院内死亡率(2例[5%] vs 4例[6.1%],P=1)均无差异。
- 1年生存率(95.56% vs 90.61%,P=.48)和全因再入院率(Gray检验P=.532)相当。
- 侧开胸组早期右心衰竭显著更少(24.4% vs 53.7%,P=.004),但随访期三尖瓣反流更多(17.6% vs 0%,P=.030)且容量负荷再入院率更高(Gray检验P=.0005)。
临床怎么用
- 作者认为侧开胸是HeartMate3植入的安全但未必优于正中胸骨切开的替代方案,因其无法同期行三尖瓣修复,可能增加晚期三尖瓣反流和容量负荷再入院风险。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to compare outcomes after left ventricular assist device implantation performed via median sternotomy or lateral thoracotomy. METHODS: We retrospectively analyzed 222 adult patients with the HeartMate3 (Abbott Lab) left ventricular assist device implanted between November 2014 and November 2021. Outcomes stratified by surgical approach were evaluated in propensity score-matched groups. The primary outcome was 1-year survival. Secondary outcomes included in-hospital morbidity and mortality, readmissions, and significant valvular regurgitation. RESULTS: Our cohort consisted of 60 patients (27%) who underwent lateral thoracotomy and 162 patients (73%) who underwent median sternotomy. Propensity score matching compared 45 patients who underwent lateral thoracotomy with 68 patients who underwent median sternotomy. There were no differences in intensive care unit or hospital stay duration (median, 10 vs 11 days, P = .58; 46 vs 40 days, P = .279), time to extubation (median, 2 days, P = .627), vasoactive-inotropic scores at intensive care unit arrival (18.20 vs 16.60, P = .654), or in-hospital mortality (2 [5%] vs 4 [6.1%] patients, P = 1). One-year survival (95.56% vs 90.61%, P = .48) and all-cause hospital readmission rate (Gray's test: P = .532) were also comparable. Patients who underwent lateral thoracotomy had significantly less early right ventricular failure (24.4% vs 53.7%, P = .004), although they had more follow-up tricuspid regurgitation (17.6% vs 0%, P = .030) and volume overload readmissions (Gray's test: P = .0005). CONCLUSIONS: Our data suggest that lateral thoracotomy is a safe although not necessarily superior alternative to median sternotomy for HeartMate 3 implantation in the perioperative and postoperative periods, because it precludes concomitant tricuspid valve repairs and may be associated with increased risk of late tricuspid regurgitation and volume overload readmissions.
引用
- Vinogradsky A, Ning Y, Kurlansky P, et al. Less is better? Comparing effects of median sternotomy and thoracotomy surgical approaches for left ventricular assist device implantation on postoperative outcomes and valvulopathy. J Thorac Cardiovasc Surg. 2022. PMID: 36008179. doi:10.1016/j.jtcvs.2022.04.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。